{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:23:15Z","timestamp":1761920595295,"version":"build-2065373602"},"reference-count":64,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["#918.66.628","#918.18.627"],"award-info":[{"award-number":["#918.66.628","#918.18.627"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001117","name":"amfAR, The Foundation for AIDS Research","doi-asserted-by":"publisher","award":["109514-61-RKVA","108683-55-RKMT"],"award-info":[{"award-number":["109514-61-RKVA","108683-55-RKMT"]}],"id":[{"id":"10.13039\/100001117","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011103","name":"Sixth Framework Programme","doi-asserted-by":"publisher","award":["037611"],"award-info":[{"award-number":["037611"]}],"id":[{"id":"10.13039\/100011103","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Seventh Framework Programme","award":["201433"],"award-info":[{"award-number":["201433"]}]},{"DOI":"10.13039\/100007553","name":"Aids Fonds","doi-asserted-by":"publisher","award":["2012041"],"award-info":[{"award-number":["2012041"]}],"id":[{"id":"10.13039\/100007553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["314730_152663","314730_172790","PZ00P3-142411","BSSGI0_155851","33CS30_148522"],"award-info":[{"award-number":["314730_152663","314730_172790","PZ00P3-142411","BSSGI0_155851","33CS30_148522"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Understanding the factors involved in the development of broadly neutralizing antibody (bNAb) responses in natural infection can guide vaccine design aimed at eliciting protective bNAb responses. Most of the studies to identify and study the development of bNAb responses have been performed in individuals who had become infected via homo- or heterosexual HIV-1 transmission; however, the prevalence and characteristics of bNAb responses in injecting drug users (IDUs) have been underrepresented. We retrospectively studied the prevalence of bNAb responses in HIV-1 infected individuals in the Amsterdam Cohort, including 50 male and 35 female participants who reported injecting drug use as the only risk factor. Our study revealed a significantly lower prevalence of bNAb responses in females compared to males. Gender, transmission route and CD4+ count at set point, but not viral load, were independently associated with the development of bNAb responses in IDUs. To further explore the influences of gender in the setting of IDU, we also looked into the Swiss 4.5k Screen. There we observed lower bNAb responses in female IDUs as well. These results reveal that the emergence of bNAbs may be dependent on multiple factors, including gender. Therefore, the effect of gender on the development of bNAb responses is a factor that should be taken into account when designing vaccine efficacy trials.<\/jats:p>","DOI":"10.3390\/v11040384","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T10:44:06Z","timestamp":1556189046000},"page":"384","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users"],"prefix":"10.3390","volume":"11","author":[{"given":"Zelda","family":"EULER","sequence":"first","affiliation":[{"name":"Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom L.","family":"VAN DEN KERKHOF","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands"},{"name":"Department of Medical Microbiology, AMC, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger D.","family":"KOUYOS","sequence":"additional","affiliation":[{"name":"Institute of Medical Virology, University of Zurich, CH-8057 Zurich, Switzerland"},{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH-8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien C.","family":"TULLY","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd M.","family":"ALLEN","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"TRKOLA","sequence":"additional","affiliation":[{"name":"Institute of Medical Virology, University of Zurich, CH-8057 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogier W.","family":"SANDERS","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, AMC, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands"},{"name":"Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanneke","family":"SCHUITEMAKER","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3422-8161","authenticated-orcid":false,"given":"Marit J.","family":"VAN GILS","sequence":"additional","affiliation":[{"name":"Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands"},{"name":"Department of Medical Microbiology, AMC, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-030409-101256","article-title":"The role of antibodies in HIV vaccines","volume":"28","author":"Mascola","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2010.09.011","article-title":"Induction of immunity to human immunodeficiency virus type-1 by vaccination","volume":"33","author":"McElrath","year":"2010","journal-title":"Immunity"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.coi.2010.02.012","article-title":"Rational antibody-based HIV-1 vaccine design: Current approaches and future directions","volume":"22","author":"Walker","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.0630530100","article-title":"Rapid evolution of the neutralizing antibody response to HIV type 1 infection","volume":"100","author":"Richman","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1086\/651144","article-title":"Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression","volume":"201","author":"Euler","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/JVI.02036-08","article-title":"Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection","volume":"83","author":"Sather","year":"2009","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"HIV-1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified Using a High Throughput Neutralization Assay Together with an Analytical Selection Algorithm","volume":"83","author":"Simek","year":"2009","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/QAD.0000000000000228","article-title":"Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers","volume":"28","author":"Euler","year":"2014","journal-title":"AIDS"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1128\/JVI.01762-08","article-title":"Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C","volume":"82","author":"Binley","year":"2008","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1128\/JVI.01482-09","article-title":"Breadth of human immunodeficiency virus-specific neutralizing activity in sera: Clustering analysis and association with clinical variables","volume":"84","author":"Klein","year":"2010","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1128\/JVI.06091-11","article-title":"Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity","volume":"86","author":"Euler","year":"2012","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","article-title":"Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection","volume":"28","author":"Hraber","year":"2014","journal-title":"AIDS"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Landais, E., Huang, X., Havenar-Daughton, C., Murrell, B., Price, M.A., Wickramasinghe, L., Ramos, A., Bian, C.B., Simek, M., and Allen, S. (2016). Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005369"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/nm.4187","article-title":"Determinants of HIV-1 broadly neutralizing antibody induction","volume":"22","author":"Rusert","year":"2016","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1128\/JVI.00198-11","article-title":"The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection","volume":"85","author":"Gray","year":"2011","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Mikell, I., Sather, D.N., Kalams, S.A., Altfeld, M., Alter, G., and Stamatatos, L. (2011). Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog., 7.","DOI":"10.1371\/annotation\/8b3b24b5-d4ed-483a-b233-0a88513ad499"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.tim.2014.08.006","article-title":"In vivo protection by broadly neutralizing HIV antibodies","volume":"22","author":"Sanders","year":"2014","journal-title":"Trends Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies","volume":"6","author":"Mascola","year":"2000","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11181","DOI":"10.1073\/pnas.1103012108","article-title":"Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody","volume":"108","author":"Burton","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nm.1974","article-title":"Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques","volume":"15","author":"Hessell","year":"2009","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hessell, A.J., Rakasz, E.G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D.N., Koff, W.C., Watkins, D.I., and Burton, D.R. (2009). Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000433"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1128\/JVI.00491-12","article-title":"A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques","volume":"86","author":"Moldt","year":"2012","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"eaao4235","DOI":"10.1126\/scitranslmed.aao4235","article-title":"Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail","volume":"9","author":"Julg","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12746","article-title":"Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia","volume":"503","author":"Shingai","year":"2013","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tim.2014.12.007","article-title":"Virological features associated with the development of broadly neutralizing antibodies to HIV-1","volume":"23","author":"Moore","year":"2015","journal-title":"Trends Microbiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/QAD.0b013e32833243e7","article-title":"Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression","volume":"23","author":"Euler","year":"2009","journal-title":"AIDS"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/imr.12504","article-title":"Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies","volume":"275","author":"Borrow","year":"2017","journal-title":"Immunol Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"298ra120","DOI":"10.1126\/scitranslmed.aab3964","article-title":"Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection","volume":"7","author":"Yamamoto","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.immuni.2013.08.031","article-title":"Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses","volume":"39","author":"Locci","year":"2013","journal-title":"Immunity"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1742-4690-10-102","article-title":"HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity","volume":"10","author":"Feenstra","year":"2013","journal-title":"Retrovirology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1128\/JVI.01149-09","article-title":"Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression","volume":"83","author":"Piantadosi","year":"2009","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Richardson, S.I., Chung, A.W., Natarajan, H., Mabvakure, B., Mkhize, N.N., Garrett, N., Abdool Karim, S., Moore, P.L., Ackerman, M.E., and Alter, G. (2018). HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1006987"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20180246","article-title":"Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity","volume":"215","author":"Kadelka","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Euler, Z., van Gils, M.J., Boeser-Nunnink, B.D., Schuitemaker, H., and van Manen, D. (2013). Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054684"},{"key":"ref_40","first-page":"43","article-title":"Functional evidence for effects of drugs of abuse on infection and immune responses","volume":"162","author":"Donahoe","year":"1996","journal-title":"Nida Res. Monogr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0376-8716(00)00180-0","article-title":"Substance abuse and the immune system","volume":"62","author":"Donahoe","year":"2001","journal-title":"Drug Alcohol Depend."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-4684-5925-8_16","article-title":"Effects of cocaine and other drugs of abuse on immune function","volume":"288","author":"Donahoe","year":"1991","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.imbio.2010.06.001","article-title":"B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases","volume":"216","author":"Zagon","year":"2011","journal-title":"Immunobiology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/infdis\/158.3.615","article-title":"Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men","volume":"158","author":"Lange","year":"1988","journal-title":"J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/QAD.0b013e32831db247","article-title":"Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection","volume":"23","author":"Kootstra","year":"2009","journal-title":"AIDS"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002030-198802000-00010","article-title":"Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam","volume":"2","author":"Coutinho","year":"1988","journal-title":"AIDS"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1128\/jcm.29.9.1804-1811.1991","article-title":"Rapid purification of hepatitis B virus DNA from serum","volume":"29","author":"Boom","year":"1991","journal-title":"J. Clin. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Giorgi, E.E., Funkhouser, B., Athreya, G., Perelson, A.S., Korber, B.T., and Bhattacharya, T. (2010). Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. Bmc Bioinform., 11.","DOI":"10.1186\/1471-2105-11-532"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Tully, D.C., Ogilvie, C.B., Batorsky, R.E., Bean, D.J., Power, K.A., Ghebremichael, M., Bedard, H.E., Gladden, A.D., Seese, A.M., and Amero, M.A. (2016). Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005619"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","first-page":"341","article-title":"Modeling sequence evolution in acute HIV-1 infection","volume":"261","author":"Lee","year":"2009","journal-title":"J. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00002030-199705000-00010","article-title":"Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study","volume":"11","author":"Prins","year":"1997","journal-title":"AIDS"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1086\/654816","article-title":"Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine","volume":"202","author":"Gilbert","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/infdis\/jiu633","article-title":"Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa","volume":"211","author":"Bandawe","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1086\/425518","article-title":"Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines","volume":"190","author":"Montefiori","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/QAI.0b013e3182100c1b","article-title":"Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity","volume":"57","author":"Sajadi","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00126334-200309010-00012","article-title":"Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion","volume":"34","author":"Collaboration","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00281-018-0726-5","article-title":"Sex differences in vaccine-induced humoral immunity","volume":"41","author":"Fischinger","year":"2018","journal-title":"Semin Immunopathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.immuni.2017.05.007","article-title":"Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches","volume":"46","author":"Pauthner","year":"2017","journal-title":"Immunity"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1128\/JVI.00077-10","article-title":"Wide variation in the multiplicity of HIV-1 infection among injection drug users","volume":"84","author":"Bar","year":"2010","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1086\/652702","article-title":"A substantial transmission bottleneck among newly and recently HIV-1-infected injection drug users in St Petersburg, Russia","volume":"201","author":"Masharsky","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Cortez, V., Odem-Davis, K., McClelland, R.S., Jaoko, W., and Overbaugh, J. (2012). HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002611"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.celrep.2018.03.082","article-title":"Superinfection Drives HIV Neutralizing Antibody Responses from Several B Cell Lineages that Contribute to a Polyclonal Repertoire","volume":"23","author":"Williams","year":"2018","journal-title":"Cell Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1089\/aid.2015.0324","article-title":"The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype","volume":"32","author":"Cornelissen","year":"2016","journal-title":"Aids Res. Hum. Retrovir."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/4\/384\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:47:03Z","timestamp":1760186823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/4\/384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,25]]},"references-count":64,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["v11040384"],"URL":"https:\/\/doi.org\/10.3390\/v11040384","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2019,4,25]]}}}